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ANGIOSARCOMA OF THE RIGHT ATRIUM: A CASE REPORT
C. D’Addetta a, T.P. Latiano a, A. Piano a, G. Di Maggio a, C.M. Di
Micco a, M.P. Romano a, L.F. Tozzi a, M. Bisceglia b, E.
Maiello a. aOncology Unit, IRCCS Casa Sollievo della Sofferenza, San
Giovanni Rotondo, Italy. bPathology Unit, IRCCS Casa Sollievo della
Sofferenza, San Giovanni Rotondo, Italy.
Background: Primary cardiac neoplasm occur rarely and most
of them are benign. Malignant tumours including angiosarcoma
are extremely rare and have a non specific clinical presentation
and a poor prognosis. Case presentation: We report a case of angi-
osarcoma of the right atrium presenting on October 2007 progres-
sive exertional dyspnea and edema of extremities. The patient
was a 59-year-old woman. Echocardiography, chest computed
tomography (CT) revealed a big mass in the right atrium
(7  6 cm), partially infiltrating the epicardium fat with concomi-
tant pericardial effusion. Moreover, CT abdomen revealed multi-
ple liver metastases. The pt underwent median sternotomy and
at the time of exploration, the mass was found in the right atrium
with infiltrating the atrioventricular junction. The pathological
diagnosis was angiosarcoma. Immunohistochemistry showed
the neoplastic cells to be reactive for the endothelial cell markers
CD31 and CD34, and negative for the epithelial cell marker cyto-
keratin, supporting the diagnosis of angiosarcoma. Her perfor-
mance status was 2 (ECOG scale). The pt agreed to
chemotherapy with ifosfamide (3.000 mg/m2 on day 1, 2, 3) and
epirubicin (90 mg/m2 on day 1), every 3 weeks. After 3 courses
of therapy, CT showed a remarkable liver metastases reduction
(PR). Further, 3 cycles of chemotherapy was been administered
and restaging evaluation imaging revealed only one liver metas-
tase. Treatment is still ongoing and the pt is asymptomatic and
alive with disease to seven months since diagnosis. Conclusion:
The optimum treatment plan is poorly defined in patients with
this presentation of angiosarcoma. However, in our experience
a good response to chemotherapy treatment was observed.
doi:10.1016/j.ejcsup.2008.06.081
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Dermatofibrosarcoma protuberans (DFSP) is a cutaneous low-
grade malignancy with a high recurrence rate and that rarely gen-
erates distant metastases. In most cases this tumour is associated
with a chromosomal translocation involving the COL1A1 gene on
chromosome 17 and the platelet-derived-growth-factor B gene on
chromosome 22, generating a fusion gene that constitutively acti-
vates the PDGF receptor (PDGFR). In the early stages of disease
traditional surgery (wide excision) or Mohs micrographic surgery
represents the standard of care. When surgical margins are posi-
tive, postoperative radiotherapy is a valuable option. For several
decades, treatment of advanced disease has been largely unsuc-
cessful because of the relatively resistance to conventional cyto-
toxic drugs. Recently it has been shown that inhibiting PDGFR
with imatinib can induce a high response rate in case of unresec-
table or metastatic disease. We saw a young man with a DFSP of
the back that underwent tumour resection in 1987. In 1997 a local
recurrence was excised without postoperative radiotherapy. The
patient came to our attention on January 2004 when the tumour
presented secondary lung lesions. On February 2004 the patient
underwent a double atypical left lung resection while other smal-
ler lesions were still present. Molecular analysis showed a muta-
tion of the PDGFRb gene. Therefore on July 2004 he started
treatment with imatinib 400 mg/day p.o. and a significant PR
was observed after just 2 months of treatment. On June 2007
residual lung lesions were resected and the histological examina-
tion did not show any malignant cell. The patient is now on treat-
ment and free of disease. Although the treatment of DFSP has
significantly improved in the last years, it is likely that a better
knowledge of molecular biology will improve response rates and
make it possible to discover new effective targeted agents.
doi:10.1016/j.ejcsup.2008.06.082
doi:10.1016/S1359-6349(08)00146-8
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